Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Rocca, Maria A.
ALLEGRO Study Group
MetadataShow full item record
BACKGROUND Two proof-of-concept clinical trials have provided evidence that laquinimod reduces disease activity in patients with relapsing–remitting multiple sclerosis. METHODS We conducted a randomized, double-blind, phase 3 study at 139 sites in 24 countries. A total of 1106 patients with relapsing–remitting multiple sclerosis were randomly assigned in a 1:1 ratio to receive oral laquinimod at a dose of 0.6 mg once daily or placebo for 24 months. The primary end point was the annualized relapse rate during the 24-month period. Secondary end points included confirmed disability progression (defined as an increase in the score on the Expanded Disability Status Scale that was sustained for at least 3 months) and the cumulative number of gadolinium-enhancing lesions and new or enlarging lesions on T2-weighted magnetic resonance imaging. RESULTS Treatment with laquinimod as compared with placebo was associated with a modest reduction in the mean (±SE) annualized relapse rate (0.30±0.02 vs. 0.39±0.03, P = 0.002) and with a reduction in the risk of confirmed disability progression (11.1% vs. 15.7%; hazard ratio, 0.64; 95% confidence interval, 0.45 to 0.91; P = 0.01). The mean cumulative numbers of gadolinium-enhancing lesions and new or enlarging lesions on T2-weighted images were lower for patients receiving laquinimod than for those receiving placebo (1.33±0.14 vs. 2.12±0.22 and 5.03±0.08 vs. 7.14±0.07, respectively; P<0.001 for both comparisons). Transient elevations in alanine aminotransferase levels to greater than three times the upper limit of the normal range were observed in 24 patients receiving laquinimod (5%) and 8 receiving placebo (2%). CONCLUSIONS In this phase 3 study, oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing–remitting multiple sclerosis.
Is part ofThe New England Journal of Medicine, 2012, vol. 366, núm. 11, p. 1000-1009
European research projects
Showing items related by title, author, creator and subject.
Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing–Remitting Multiple Sclerosis: Quantifying the Patient’s Perspective Meca-Lallana, José E.; Maurino, Jorge; Hernández Pérez, Miguel A.; Sempere, Ángel P.; Brieva Ruiz, Luis; García-Arcelay, Elena; Terzaghi, María; Saposnik, Gustavo; Ballesteros, Javier (Springer, 2020)Crucial elements for achieving optimal long-term outcomes in multiple sclerosis (MS) are patient confidence and effective physician-patient communication. Patient-reported instruments may provide the means to fill the gap ...
Lipidome analysis in multiple sclerosis reveals protein lipoxidative damage as a potential pathogenic mechanism Gonzalo Benito, Hugo; Brieva Ruiz, Luis; Tatzber, Franz; Jové Font, Mariona; Cacabelos Barral, Daniel; Cassanyé, Anna; Lanau, Lucia; Boada Pallàs, Jordi; Serrano Casasola, José Carlos Enrique; González Mingot, Cristina; Hernández, Lourdes; Peralta Moncusí, Silvia; Pamplona Gras, Reinald; Portero Otín, Manuel (Wiley, 2012)Metabolomic and lipidomic analyses have been used for the profiling of neurodegenerative processes, both in targeted and untargeted approaches. In this work we have applied these techniques to the study of CSF samples of ...
Gonzalo Benito, Hugo; Nogueras Penabad, Lara; Gil-Sánchez, Anna; Vicente Hervás, José; Valcheva, Petya; González Mingot, Cristina; Martin-Gari, Meritxell; Canudes, Marc; Peralta Moncusí, Silvia; Solana Moga, M. José; Pamplona Gras, Reinald; Portero Otín, Manuel; Boada Pallàs, Jordi; Serrano Casasola, José Carlos Enrique; Brieva Ruiz, Luis (Frontiers Media, 2019)Literature suggests that oxidative stress (OS) may be involved in the pathogenesis of multiple sclerosis (MS), in which the immune system is known to play a key role. However, to date, the OS in peripheral lymphocytes and ...